QUINTILES EAST ASIA PTE LTD Earns Distinguished Award for Multinational Clinical Services Provider of the Year

May 19, 2006


Frost & Sullivan recognizes the company’s exemplary performance in clinical services across Asia Pacific in 2005

SINGAPORE – Quintiles, a leading world provider of clinical development services, has been awarded the Multinational Clinical Trials Service Provider of the Year and Multinational CRO of the Year at the prestigious 2006 Frost & Sullivan Asia Pacific Healthcare Best Practice Awards banquet. These awards were given in recognition of the multinational CRO’s exemplary performance in clinical services across Asia Pacific region in 2005.

Quintiles East Asia Pte Ltd was established in 1995 in Singapore as a wholly owned subsidiary of Quintiles Transnational Corporation and today operates throughout the Asia-Pacific region. It offers the full spectrum of clinical development services, including clinical research, laboratory services, regulatory affairs and consulting to pharmaceutical and biotechnology firms.

Anand Tharmaratnam, M.D., Quintiles East Asia’s CEO and Head of Asia Pacific Clinical Development, received the Multinational CRO of the Year award, while the Multinational Clinical Trials Service Provider of the Year award was received by. Michael Stibilj, Executive Director, Clinical Development SEA, Taiwan and Korea.

“Our chairman and founder, Dr. Dennis Gillings, made a decision in the early 1990’s to invest in an infrastructure and organization throughout Asia Pacific. In parallel, government institutions such as the Singapore EDB have created a climate ideal for drug development, and our clients are conducting more development in the region. The combination of all of the above and our expert team of development professionals have resulted in a truly best in class service offering”, said Dr Anand Tharmaratnam.

“Asia Pacific has all the right constituents to deliver world class clinical development -- lots of patients, a disease spectrum that includes that of the developing and developed world, a great hospital infrastructure, highly motivated investigators and a stable regulatory environment,” said Mr. Michael Stibilj.

Clinical Trials constitute a large portion of the services and revenues of Quintiles East Asia. Last year, Quintiles conducted 70-80 new clinical trials in the region, with over 200 trials ongoing at time of press. In 2005, clinical development business growth in the region was over 35%.

Quintiles East Asia offers clinical trials services in all four phases of drug development to pharmaceutical and biotech companies. It has approximately 320 clinical research staff in the region.

“Quintiles East Asia offers the full spectrum of clinical development services in the Asia Pacific region with clinical trials forming a major portion of these services. It has invested heavily in expanding its geographic scope within the region and has established close links with hospitals and investigators, to facilitate patient recruitment and to provide faster, and more efficient, clinical trials,” says Frost & Sullivan’s Program Manager, Ms. Shruti Dwivedi.

“Already leading the clinical research outsourcing market in Asia Pacific, Quintiles continues to successfully grow its clinical trial services in scope and size, and was hence selected as the recipient for the Multinational Clinical Trial Services Provider of the Year award, ”Ms. Dwivedi continues.

Quintiles offers clinical development services in diverse therapeutic areas including Central Nervous System (CNS), Oncology, Cardiovascular, Thrombosis, Respiratory, Urology, Autoimmune, Endocrinology and Infectious diseases. In 2005, Quintiles East Asia saw substantial growth in revenue, driven by a significant increase in the number of trials conducted in the region. In the same year, Quintiles set up offices in Indonesia and Vietnam, adding to its operations in Australia, Malaysia, Philippines, Taiwan, China, Korea, New Zealand, Singapore and Thailand.

“By continually widening and strengthening its service offerings, Quintiles has gained market leadership in the Asia Pacific region. Due to its excellence in service and rapid growth in terms of clinical trials, revenues and operations, it has been selected as the recipient for the Multinational CRO of the Year award,” adds Ms. Dwivedi.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

About Quintiles

Quintiles Transnational is the global leader in pharmaceutical services, improving healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of the pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000 specialized employees and offices in 50 countries. For more information visit the company’s Web site at www.quintiles.com.

Contact Information

Jasminder Kaur

Corporate Communications

Frost & Sullivan

Contact via E-mail